Peptides for Longevity: BPC-157, TB-500, Sermorelin, and the Evidence Gap That Matters
Peptide therapies occupy a unique and uncomfortable position in longevity medicine: widely used by longevity-oriented physicians and biohackers, producing compelling anecdotal results and interesting preclinical data, but almost entirely lacking the randomized controlled trial evidence in humans that would allow confident clinical recommendations. This is an honest assessment of what the evidence shows - and does not show.
- Peptides used in longevity medicine are short chains of amino acids - typically 5 to 50 amino acids - that mimic or modulate endogenous signaling molecules. They are generally administered by subcutaneous injection (for most therapeutic peptides) or orally (for some research peptides) and have short half-lives requiring frequent dosing.
- BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protein in human gastric juice. In animal studies it speeds healing of tendons, ligaments, muscle, bone and gut tissue, but no randomized controlled trial in humans has been published.
- GH secretagogues (sermorelin, ipamorelin, CJC-1295, tesamorelin) stimulate the body's own growth hormone release and raise IGF-1. Only tesamorelin is FDA-approved, for excess abdominal fat in people with HIV; long-term benefits and safety in healthy older adults are unproven.
- Most longevity peptides are not FDA-approved. Many were restricted for compounding in 2023; in July 2026 an FDA advisory committee recommended returning BPC-157, TB-500 and four others to the list pharmacies may compound, and the FDA has not yet acted. Compounding eligibility is not drug approval, and the purity of non-pharmaceutical products remains a real safety concern.
- The honest evidence assessment: tesamorelin has solid trial data in its approved use; other GH secretagogues raise GH and IGF-1 but lack outcome data. BPC-157 has striking animal data and no published human RCT. Thymosin beta-4, the parent of TB-500, has been tested in small human wound-healing trials; TB-500 itself has not. All use beyond approved indications is experimental.
Peptide therapies represent one of the most rapidly evolving and evidence-poor domains in longevity medicine. The interest is understandable: endogenous peptides are extraordinarily important signaling molecules - insulin, GLP-1, GH-releasing hormone, and hundreds of others coordinate metabolism, growth, repair, and immune function across the entire body. Pharmaceutical-grade versions of naturally occurring peptides (insulin, semaglutide, tesamorelin) have transformed medicine.1 The logical extension - that additional peptides with interesting preclinical biology could provide clinical benefit - is plausible. But plausibility is not evidence, and the evidence gap in longevity peptides is significant.
BPC-157: The Most Discussed Research Peptide
BPC-157 is a synthetic peptide consisting of 15 amino acids, derived from a sequence found in human gastric juice protein. It was first characterized by Predrag Sikiric at the University of Zagreb beginning in the 1990s. The preclinical literature on BPC-157 is extensive and consistently positive, though most of it comes from one research group in Zagreb: it accelerates healing of tendons, ligaments, muscle, bone, and gut tissue in rat and mouse models; demonstrates neuroprotective effects after traumatic brain injury and spinal cord damage; reverses organ damage from toxins including NSAIDs and alcohol; has anti-inflammatory effects via nitric oxide and growth factor signaling; and produces anxiolytic and antidepressant effects in animal behavioral models.2
The human evidence is essentially absent. No randomized controlled trial of BPC-157 in humans has been published; the human data consist of a few small, uncontrolled reports. Compelling animal data has repeatedly failed to translate into human benefit in other areas, from antioxidant megadosing onwards. BPC-157 is used experimentally, with anecdotal reports of faster recovery from musculoskeletal injuries, and should be treated as experimental until human trials report.
GH Secretagogues: The Most Developed Human Evidence
Growth hormone secretagogues (GHS) are peptides that stimulate GH release from the pituitary via binding to the ghrelin receptor (GHSR) or GHRH receptor. The major classes include: GHRH analogs (sermorelin, CJC-1295, tesamorelin) which bind the GHRH receptor and stimulate physiological pulsatile GH release; and GHRPs (ipamorelin, hexarelin, GHRP-2, GHRP-6) which bind the ghrelin receptor (GHSR-1a) and also stimulate GH release, sometimes with appetite stimulation as a side effect.3
Tesamorelin is the most clinically established GH secretagogue - it is FDA-approved for HIV-associated lipodystrophy and has published RCT data in this population showing improved body composition, reduced visceral fat, and improved lipid profiles. Sermorelin was previously FDA-approved but is no longer marketed as an approved drug in the US; it has been used off-label in longevity medicine. Ipamorelin and CJC-1295 are widely used in longevity practice but have little published human outcome data.
TB-500 (Thymosin Beta-4)
Thymosin beta-4 (TB4) is a naturally occurring 43-amino acid peptide involved in actin polymerization, cell migration, and tissue repair. TB-500 is a synthetic fragment of TB4 that is claimed to retain its tissue-healing properties. TB4 itself has been studied in human wound healing trials with modest positive results. The synthetic TB-500 fragment has a less developed human evidence base. Both compounds are of significant interest as potential muscle and tendon repair agents, but the human clinical data is insufficient to draw confident conclusions about efficacy or optimal dosing in the longevity context.4
The Quality and Regulatory Reality
The regulatory status of most longevity peptides creates a quality control problem that deserves explicit acknowledgment. Peptides sourced through compounding pharmacies or research chemical suppliers are not subject to the manufacturing standards required of FDA-approved pharmaceuticals. Without those standards, content and purity cannot be assumed: when researchers bought semaglutide from illegal online pharmacies, every vial was probably substandard or falsified, with purity of 7.7 to 14.4 percent against the 99 percent on the label and endotoxin in every sample.5 This means the risks of peptide use extend beyond the theoretical risks of the compounds themselves to include risks from impurities and inaccurate dosing.
A 2026 update: the regulatory picture shifted meaningfully this year. After restricting a long list of peptides in 2023, the FDA began reversing course in early 2026, and on July 23–24, 2026, an FDA advisory committee recommended BPC-157, TB-500, MOTS-C and three others for the list of substances pharmacies may legally compound, against the advice of FDA staff; the FDA has not yet acted on the recommendations (AJMC; NCPA). It is essential to read this correctly: the decision concerns legal compounding eligibility, not FDA drug approval, and it changes nothing about the underlying human evidence — which remains thin for most of these compounds. We cover the details, and the crucial distinction between reclassification and approval, in The FDA Peptide Reclassification, Explained.
The excitement surrounding peptide therapies in longevity circles is understandable - the preclinical data for some compounds, particularly BPC-157, is genuinely striking. But the history of longevity science is littered with compounds that demonstrated extraordinary effects in cell culture and animal models and failed to produce clinical benefit in humans. Antioxidants, resveratrol, and dozens of other compounds followed this trajectory. The appropriate response to compelling preclinical data is well-designed human trials, not widespread experimental use in the absence of such trials. Anyone using peptide therapies outside of approved clinical indications should understand they are participating in an uncontrolled experiment without clear safety or efficacy data.
References
- 1Muttenthaler M, et al. "Trends in peptide drug discovery." Nat Rev Drug Discov. 2021;20(4):309-325. PubMed · DOI
- 2Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Curr Neuropharmacol. 2016;14(8):857-865. PubMed · DOI
- 3Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sex Med Rev. 2018;6(1):45-53. PubMed · DOI
- 4Goldstein AL, et al. "Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications." Expert Opin Biol Ther. 2012;12(1):37-51. PubMed · DOI
- 5Ashraf AR, et al. "Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study." J Med Internet Res. 2024;26:e65440. PubMed · DOI